ImmunoVaccine Technologies Receives European Patent Allowance
All of the claims filed for the patent were allowed following modification of claims 43, 44 and 45. These claims were modified to conform to European patent presentation.
Upon receiving the notification Dr. Warwick Kimmins, President and CEO stated, "The issuance of the European patent complements the US patent protection for our VacciMax(R) vaccine platform technology and is good news for IVT's shareholders and our industry partners."
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.